|
EP2099821A2
|
|
Gene and protein that homes to developing microvessels
|
|
US2004048295A1
|
|
Heregulin-like factor antibodies
|
|
WO03066639A2
|
|
Methods for identifying targeting domains and methods and compositions comprising the same
|
|
AU2002346049A1
|
|
Coactivators in the diagnosis and treatment of breast cancer
|
|
AU8494201A
|
|
Small molecule inhibitors targeted at bcl-2
|
|
CA2398358A1
|
|
The neurosteroid dhea as a marker for neuropathologies
|
|
WO0023590A2
|
|
INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
|
|
AU6263699A
|
|
Response regulator (cassk1)
|
|
WO0009549A2
|
|
Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use
|
|
EP1089734A2
|
|
Use of tempo and tempo derivatives for inducing cell death
|
|
WO9964057A1
|
|
Retinoic acid inducible dna sequences from lung cells
|
|
AU3096899A
|
|
Cholesterol recognition sequence
|
|
AU2223899A
|
|
G protein-related kinase mutants in essential hypertension
|
|
EP1025221A2
|
|
ErbB-4 TARGETED RIBOZYMES
|
|
US5624895A
|
|
Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
|
|
US4320768A
|
|
Computerized electro-oculographic (CEOG) system
|
